| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
227.84(M) |
| Last
Volume: |
2,211,986 |
Avg
Vol: |
2,301,679 |
| 52
Week Range: |
$0.449 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
86,265 |
122,918 |
235,260 |
541,068 |
| Total Sell Value |
$152,594 |
$177,518 |
$247,417 |
$1,284,611 |
| Total People Sold |
4 |
4 |
7 |
10 |
| Total Sell Transactions |
4 |
7 |
16 |
37 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2016-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,167 |
7,970 |
|
- |
|
| Labrucherie Gil M |
SVP & General Counsel |
• – – |
2016-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,167 |
8,757 |
|
- |
|
| Lingnau Lutz |
Director |
– • – |
2016-04-25 |
4 |
AS |
$16.27 |
$244,050 |
D/D |
(15,000) |
16,450 |
|
- |
|
| Lingnau Lutz |
Director |
– • – |
2016-04-25 |
4 |
OE |
$8.37 |
$125,550 |
D/D |
15,000 |
31,450 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2016-03-09 |
4 |
AS |
$11.79 |
$176,850 |
D/D |
(15,000) |
5,158 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2016-03-09 |
4 |
OE |
$6.65 |
$99,750 |
D/D |
15,000 |
20,158 |
|
- |
|
| Gergel Ivan |
SVP & Chief Medical Officer |
• – – |
2016-02-17 |
4 |
S |
$11.92 |
$6,628 |
D/D |
(556) |
694 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2016-02-17 |
4 |
S |
$11.92 |
$11,479 |
D/D |
(963) |
5,803 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2016-02-17 |
4 |
S |
$11.92 |
$25,592 |
D/D |
(2,147) |
13,478 |
|
- |
|
| Nicholson John |
SVP & Chief Financial Officer |
• – – |
2016-02-17 |
4 |
S |
$11.92 |
$11,479 |
D/D |
(963) |
76,319 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2016-02-17 |
4 |
S |
$11.92 |
$4,649 |
D/D |
(390) |
485 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2016-02-17 |
4 |
S |
$11.92 |
$8,535 |
D/D |
(716) |
5,158 |
|
- |
|
| Labrucherie Gil M |
SVP & General Counsel |
• – – |
2016-02-17 |
4 |
S |
$11.92 |
$9,858 |
D/D |
(827) |
6,590 |
|
- |
|
| Gergel Ivan |
SVP & Chief Medical Officer |
• – – |
2016-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,250 |
1,250 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2016-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,166 |
6,766 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2016-02-16 |
4 |
OE |
$0.00 |
$1 |
D/D |
5,625 |
15,625 |
|
- |
|
| Nicholson John |
SVP & Chief Financial Officer |
• – – |
2016-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,166 |
77,282 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2016-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
875 |
875 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2016-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,875 |
5,874 |
|
- |
|
| Labrucherie Gil M |
SVP & General Counsel |
• – – |
2016-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,166 |
7,417 |
|
- |
|
| Labrucherie Gil M |
SVP & General Counsel |
• – – |
2016-02-10 |
4 |
AS |
$11.49 |
$134,042 |
D/D |
(11,666) |
5,251 |
|
- |
|
| Labrucherie Gil M |
SVP & General Counsel |
• – – |
2016-02-10 |
4 |
OE |
$6.46 |
$75,362 |
D/D |
11,666 |
16,917 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2016-02-10 |
4 |
AS |
$11.49 |
$172,350 |
D/D |
(15,000) |
3,999 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2016-02-10 |
4 |
OE |
$6.65 |
$99,750 |
D/D |
15,000 |
18,999 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2016-02-10 |
4 |
AS |
$11.49 |
$765,992 |
D/D |
(66,666) |
10,000 |
|
- |
|
913 Records found
|
|
Page 25 of 37 |
|
|
0.01 (0.79%) 
